New hope for cancer patients who stopped responding to immunotherapy?
NCT ID NCT07219576
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 35 times
Summary
This early-phase trial is testing whether combining two drugs—retifanlimab and ruxolitinib—can safely help people with advanced lung or kidney cancer whose disease has progressed after prior immunotherapy. About 40 participants will take ruxolitinib pills twice daily and receive retifanlimab infusions every four weeks. The main goal is to find the safest dose of ruxolitinib to use with retifanlimab and to see if the combination shrinks tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Diego Moores Cancer Center
RECRUITINGLa Jolla, California, 92093, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
retifanlimab and ruxolitinib
What this could lead to
If it works, this could point toward a new treatment option for people with advanced lung or kidney cancer whose disease has worsened after immunotherapy.
What could go wrong
This is an early-phase trial with only 40 participants, so the combination may not prove effective or safe enough for wider use. Side effects from the drugs could be serious.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.